Fig. 3From: Integrating trans-omics, cellular experiments and clinical validation to identify ILF2 as a diagnostic serum biomarker and therapeutic target in gastric cancerHeatmaps of immune cell scores and comparisons between high and low biomarker expression groups. *P < 0.05, **P < 0.01, ***P < 0.001. A: ILF2; B: CHD7; C: PGM2L1Back to article page